Results 81 to 90 of about 1,121 (157)

Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab. [PDF]

J Endocr Soc
Zanchetta MB, Dahir KM, Imel EA, Carpenter TO, Sandilands K, Johnson B, Li Z, Camidge L, Rottier E, Wilkes E, Vinall E, Sader S, Jan de Beur SM.   +12 more
europepmc   +1 more source

Burosumab for X-linked Hypophosphataemia and Tumour-induced Osteomalacia in Adults. [PDF]

touchREV Endocrinol
Black S, Keen R, Bubbear J.
europepmc   +1 more source

Effectiveness, safety, and pharmacokinetics of burosumab in Chinese children with X-linked hypophosphatemia: an open-label, single-arm phase 4 study. [PDF]

JBMR Plus
Wu W, Jiang Y, Zhang Z, Liu L, Qiu W, Ji Y, Sugimoto M, Yung C, Qiu C, Kuriki M, Luo X, Xia W.   +11 more
europepmc   +1 more source

XLH Matters 2024 GCC Edition: Insights and Recommendations to Improve Outcomes for People Living With XLH in the Gulf Region. [PDF]

Clin Med Insights Endocrinol Diabetes
Seefried L, Al Badi M, Frookh H, Al-Sagheir A, Fiad TM, Deeb A, Al Sumaily A, Attia N, Habeb A, Alzahrani A, Mughal MZ.   +10 more
europepmc   +1 more source

Burosumab use in fibroblast growth factor-23-mediated hypophosphatemia in McCune-Albright syndrome/fibrous dysplasia. [PDF]

JCEM Case Rep
Alsayed Hasan M, Al Mukaddam M.
europepmc   +1 more source

Burosumab an emerging therapy in TIO: a local clinical survey and a systematic review with individual patient data analysis. [PDF]

Front Endocrinol (Lausanne)
Vergatti A, Abate V, Zarrella AF, Fieramosca N, De Filippo G, Merlotti D, Gennari L, Menale C, D'Elia L, Rendina D.   +9 more
europepmc   +1 more source

Real-world impact of treatment on growth in children with X-linked hypophosphatemia.

J Clin Endocrinol Metab
Fukumoto S, Haffner D, Imel EA, Ozono K, Brandi ML, Ishii H, Li Z, Sandilands K, Joos-Vandewalle P, Lee C, Kanematsu M, McCullough KP, Carpenter TO.   +12 more
europepmc   +1 more source

Burosumab treatment in an adult with FGF23-mediated hypophosphatemia due to cutaneous skeletal hypophosphatemia syndrome. [PDF]

J Endocr Soc
Tosi LL, Rajah EN, Gillies AP, Kim M, Reid K, Gafni RI.   +5 more
europepmc   +1 more source

Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing

Journal of Bone and Mineral Research, 2020
Jan de Beur, Suzanne M., Miller, Paul D., Weber, Thomas J., Peacock, Munro, Insogna, Karl, Kumar, Rajiv, Rauch, Frank, Luca, Diana, Cimms, Tricia, Scott Roberts, Mary, San Martin, Javier, Carpenter, Thomas O.   +11 more
openaire   +2 more sources

X-linked hypophosphatemia in the presence of a <i>CLDN16</i> variant: implications for renal handling and disease severity. [PDF]

JCEM Case Rep
Jang SA, Kim KM, Rhee Y.
europepmc   +1 more source